NCT06947590View on ClinicalTrials.gov

Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 20, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions

HCM - Hypertrophic CardiomyopathyMavacamten

Interventions

DRUG

mavacamten

Patients in this group were treated with Mavacamten, starting at an initial dose of 2.5 mg, administered orally once daily. Subsequent doses were adjusted based on changes in pressure gradients and cardiac function observed during follow-up.

Trial Locations (1)

Unknown

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Xu Liu

OTHER

NCT06947590 - Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter